Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study - PubMed (original) (raw)
Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study
Henriette T Horsdal et al. Diabetes Metab Res Rev. 2009 Sep.
Abstract
Background: The cardiovascular safety, including risk of myocardial infarction (MI), of individual sulfonylureas (SUs) may differ. It remains uncertain whether treatment with individual SUs influences prognosis following MI.
Methods: We conducted a nationwide population-based follow-up study among all Danish patients hospitalized with first-time MI from 1996 to 2004. From the national health databases, we identified 3930 MI patients who used SUs at the time of admission. We computed mortality rates and rates of MI and heart failure readmission according to type of SU and used Cox's proportional hazards regression analysis to compute hazard ratios (HRs) as estimates of relative risk controlling for differences in prognostic covariates.
Results: The 30-day and 1-year mortality after MI among SU users was 22.0% and 35.3%, respectively. We found no substantial differences in 30-day and 1-year mortality among users of different SUs. Use of gliclazide in monotherapy showed a trend towards lower mortality; adjusted HR of 1-year mortality 0.70 (95% CI: 0.48-1.00). Users of the different SUs appeared to have similar risks of new MI and heart failure following MI.
Conclusions: The prognosis after MI was not substantially influenced by the choice of SU.
Similar articles
- Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
Horsdal HT, Mehnert F, Rungby J, Johnsen SP. Horsdal HT, et al. J Stroke Cerebrovasc Dis. 2012 Nov;21(8):717-25. doi: 10.1016/j.jstrokecerebrovasdis.2011.03.007. Epub 2011 May 4. J Stroke Cerebrovasc Dis. 2012. PMID: 21536457 - Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C. Schramm TK, et al. Circulation. 2008 Apr 15;117(15):1945-54. doi: 10.1161/CIRCULATIONAHA.107.720847. Epub 2008 Mar 31. Circulation. 2008. PMID: 18378618 - Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. McAfee AT, et al. Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):711-25. doi: 10.1002/pds.1443. Pharmacoepidemiol Drug Saf. 2007. PMID: 17551989 - Oral sulfonylureas and CV mortality.
Aronow WS. Aronow WS. Geriatrics. 2004 Sep;59(9):45-6, 49. Geriatrics. 2004. PMID: 15461238 Review. No abstract available. - [Acute coronary syndrome in patients with type 2 diabetes mellitus].
Ametov AS, P'ianykh OP, Aslandziia EN. Ametov AS, et al. Ter Arkh. 2011;83(9):66-70. Ter Arkh. 2011. PMID: 22145391 Review. Russian.
Cited by
- Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review.
Sahin I, Bakiner O, Demir T, Sari R, Atmaca A. Sahin I, et al. Diabetes Ther. 2024 Aug;15(8):1687-1716. doi: 10.1007/s13300-024-01612-8. Epub 2024 Jun 27. Diabetes Ther. 2024. PMID: 38935188 Free PMC article. Review. - The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells.
Altabas V, Marinković Radošević J, Špoljarec L, Uremović S, Bulum T. Altabas V, et al. Biomedicines. 2023 Nov 14;11(11):3051. doi: 10.3390/biomedicines11113051. Biomedicines. 2023. PMID: 38002051 Free PMC article. Review. - Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care.
Rungby J, Schou M, Warrer P, Ytte L, Andersen GS. Rungby J, et al. Cardiovasc Endocrinol. 2017 Dec;6(4):145-151. doi: 10.1097/XCE.0000000000000135. Epub 2017 Oct 31. Cardiovasc Endocrinol. 2017. PMID: 29276653 Free PMC article. - Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.
Pladevall M, Riera-Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S. Pladevall M, et al. BMC Cardiovasc Disord. 2016 Jan 15;16:14. doi: 10.1186/s12872-016-0187-5. BMC Cardiovasc Disord. 2016. PMID: 26769243 Free PMC article. - Prevalence and temporal pattern of hospital readmissions for patients with type I and type II diabetes.
Liu X, Liu Y, Lv Y, Li C, Cui Z, Ma J. Liu X, et al. BMJ Open. 2015 Nov 2;5(11):e007362. doi: 10.1136/bmjopen-2014-007362. BMJ Open. 2015. PMID: 26525716 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical